Ciprofloxacin is powerful against Gram-negative bacteria and some Gram-positive, making it effective for acute exacerbations of chronic bronchitis. Azithromycin, a macrolide, is better suited for community-acquired pneumonia and chronic respiratory conditions due to its anti-inflammatory properties and good coverage against common respiratory pathogens. Overall, macrolides are often preferred due to a lower risk of serious side effects and broader effectiveness against typical respiratory infections.